ClinicalTrials.gg
RecruitingNCT07021014Updated Nov 6, 2026

NightWare and Cardiovascular Health in Women With PTSD

An interventional study of NightWare and Sham NightWare in Post Traumatic Stress Disorder, Cardiovascular Diseases and Autonomic Dysfunction, sponsored by University of Colorado, Denver. Recruiting at 2 sites in United States. Open to female participants aged 22 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 6, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
22 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Stress Disorders, Post-Traumatic by University of Colorado, Denver — 4 open to participants now, 4 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of Colorado, Denver.

Planned enrollment
9th of 12
36 · median 57
Started
2025
with 2 others
No phase
10 of 13
4 open now
Registered
13th of 13
by date

Among the 13 studies in Stress Disorders, Post-Traumatic by University of Colorado, Denver, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 with no phase, and was the 13th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

4 of the 13 studies in Stress Disorders, Post-Traumatic by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 22 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Stress Disorders, Post-Traumatic by University of Colorado, Denver, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether NightWare therapeutic intervention improves biomarkers of vascular and renal function in premenopausal women with PTSD-related nightmares, and examine whether these improvements restore them to levels observed in age-matched women without PTSD.

Read the detailed description

Women are disproportionally affected by posttraumatic stress disorder (PTSD), a debilitating mental health disorder that profoundly increases cardiovascular disease (CVD) risk. Biological processes including vascular dysfunction (i.e., impaired endothelial function, arterial stiffening), increased renin-angiotensin-aldosterone system (RAAS) activity, and altered renal vascular control and function may contribute to the pathophysiological link between PTSD and CVD. Sleep is a key regulator of cellular and tissue repair, free radical detoxification, oxidative stress, inflammation, autonomic and endocrine balance and crucial for cardiovascular health. Sleep disturbances due to nightmares are a hallmark symptom of PTSD that cause significant distress and may independently contribute to elevated CVD risk in individuals with PTSD. As such, interventions aimed at treating trauma-related nightmares are a promising therapeutic approach in ameliorating the cardiovascular consequences of PTSD.

NightWare™, a smart-watch based application that uses biometric data and vibrotactile feedback to disrupt nightmares, is an FDA approved digital therapeutic system for the treatment of nightmares in adults (≥22 years) with PTSD. While a preliminary study demonstrated that 30 days of NightWare treatment improved subjective sleep quality in Veterans, the influence of NightWare treatment on vascular and renal function in young women with PTSD-related nightmares is unknown. These investigations are critical among women who, despite having 2x greater prevalence of PTSD compared to men, and a differential progression of PTSD, CVD, and chronic kidney disease (CKD), are underrepresented in the literature.

Accordingly, the investigators will examine if the NightWare digital therapeutic system improves vascular and renal function in premenopausal women with PTSD-related nightmares, and whether these improvements restore them to levels observed in age-matched women without PTSD. We will employ 1) cross-sectional comparisons between two groups of women: those with PTSD and nightmares (PTSD group) and those without PTSD and nightmares (age-matched control group); and 2) a short-term (8-week) NightWare or sham intervention in women with nightmares related to PTSD.

03

Conditions studied

  • Post Traumatic Stress Disorder
  • Cardiovascular Diseases
  • Autonomic Dysfunction
  • Vascular Stiffness
  • Nightmare
  • Endothelial Dysfunction
  • Kidney Diseases
  • Renal Dysfunction
  • Trauma and Stressor Related Disorders

Keywords

  • Sleep
  • Trauma and Stressor Related Disorders
  • Post Traumatic Stress Disorder
  • Cardiovascular Diseases
  • Kidney Diseases
  • Renal Dysfunction
  • Autonomic Dysfunction
04

Who can participate

Ages eligible
22 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, as determined by medical history
  • Group Specific Eligibility
  • PTSD Group
  • Lifetime PTSD: screened using Primary Care PTSD Screen for (PC-PTSD-5) and confirmed via Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
  • Prior trauma exposure: screened using Brief Trauma Questionnaire (BTQ)
  • Self-report having repetitive nightmares contributing to disrupted sleep
  • Poor overall sleep quality: PSQI score 6 or higher
  • Control Group
  • No lifetime PTSD: screened using PC-PTSD-5
  • No prior trauma exposure: screened using BTQ
  • Do not self-report having repetitive nightmares contributing to disturbed sleep

Exclusion criteria

Exclusion Criteria:

  • Pre-existing (e.g., diabetes, liver, kidney disease) or unstable medical condition (e.g., uncontrolled hypertension or active CVD or cancer) or systemic illness that would interfere with interpretation of the study outcomes
  • ≥ 40 kg/m2
  • Use of medications that might influence cardiovascular or renal function (i.e., antihypertensive, lipid lowering medications, GLP-1/GIP RAs)
  • Active infection (note, anyone with an active infection would become eligible once the infection has ended)
  • Abnormal thyroid, liver, or kidney function testing during the screening examination or bloodwork. Abnormal kidney function defined as creatinine >1.3mg/dL. Abnormal liver function tests within 1.5x . UCH Clinical Lab ULN for and ALT are 39 and 52, respectively. Women with TSH levels outside of the normal range (0.5-5.0 mLU/L) will be referred to their PCP and will be allowed study entry once their TSH levels are normalized > 3 months
  • Plasma glucose >126 mg/dl under fasting conditions
  • Use of insulin or sulfonylureas
  • Pregnant, within 12 months postpartum or currently breast feeding
  • Current history of substance (excluding marijuana) or alcohol abuse per the SCID-5. Adults with past substance or alcohol use disorders will be allowed to participate.
  • Report elevated acute risk for suicidal self-directed violence warranting immediate hospitalization (e.g., suicidal ideation with intent, evaluated by the C-SSRS).
  • Shift workers
  • Diagnosis of active disorder of arousal from non-rapid eye movement sleep, rapid eye movement sleep behavior disorder, or narcolepsy
  • Nocturia that causes awakening from sleep
  • Epworth Sleepiness Scale: Question #8 score above "0" will prompt an additional question: Do you drive ("get behind the wheel") when you are drowsy? The answer must be "No" to be enrolled in the study due to safety concerns
  • Known sleep walking or acting out dreams ( to NightWare use)
  • Diagnosis or suspicion of dementia
  • Participants experiencing severe cognitive impairment or current psychiatric symptoms of such severity that would preclude participation (e.g., active psychosis, imminently suicidal)
  • Current use of vitamin/supplements (including melatonin) or anti-inflammatory medications, participants will be included if they are willing to stop taking vitamin/supplements or anti-inflammatory medications 2 weeks prior to the first vascular visit.
  • Current or planned participation in an interventional study during the present study
  • Participants must have access to wireless internet and two power outlets where they sleep
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Experimental NightWare

    In women with PTSD-related nightmares randomized to the active condition, when the stress index is reached during sleep, NightWare will intervene with varying degrees of vibratory stimulation to the watch over a variable length of time to arouse the person out of the nightmare without awakening.

    Device: NightWare

  • Sham comparator
    Sham NightWare

    In women with PTSD-related nightmares randomized to the sham condition, the NightWare intervention will not be enabled

    Device: Sham NightWare

  • No intervention
    Control Women without PTSD-related Nightmares

    Age-matched women without PTSD-related nightmares will complete baseline testing only (no intervention).

Interventions

  • DeviceNightWare

    A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.

  • DeviceSham NightWare

    NightWare decive will not deliver an intervention (i.e., no vibration)

06

What researchers measure

Primary outcomes

  1. Brachial artery flow-mediated dilation (FMD)

    FMD of the brachial artery, calculated as a percentage, is an index of vascular function. A higher number is a general indicator of better vascular function.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

Secondary outcomes

  1. Large artery elastic stiffness

    Carotid-femoral pulse wave velocity (PWV). A higher number is a general indicator of worse vascular function.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

Other outcomes

  1. Large artery elastic stiffness-carotid artery

    Carotid artery compliance using carotid artery ultrasound; a higher carotid artery compliance is a general indicator of better vascular function.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  2. Autonomic function-baroreflex sensitivity

    Cardiovagal baroreflex sensitivity (cBRS) measured using beat-to-beat time series of systolic blood pressures (finger photo-plethysmography) and R-R interval (three-lead electrocardiogram) will be recorded simultaneously at 1,000 Hz.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  3. Autonomic function- heart rate variability

    Heart rate variability

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  4. Blood pressure

    Seated blood pressure measured in mmHg

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  5. Estimated glomerular filtration rate (eGFR)

    Serum cystatin C, alongside demographic information, will be used to estimate kidney filtration of waste and excess water. A low eGFR can indicate renal dysfunction.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  6. Renal vascular control

    Peak change in renal vascular resistance in response to sympathoexcitation via cold pressor test

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  7. Renal functional reserve

    Peak change in creatinine clearance (calculated using urine creatinine, serum creatinine, urine flow rate) following ingestion of oral protein

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  8. Pittsburgh Sleep Quality Index (PSQI)

    Sleep questionnaire with a scale of 0 to 21 with a higher score indicating a significant sleep disturbance

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  9. Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A)

    Sleep questionnaire to assess frequency of seven disruptive nocturnal behaviors; scores range from 0-21 with higher scores indicating more severe PTSD-related sleep disturbances.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  10. PTSD Checklist for DSM-5 (PCL-5)

    Presence and severity of PTSD symptoms questionnaire; scores range from 0-80 with higher scores indicating more severe PTSD symptoms.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  11. Nightmare Disorder Index (NDI)

    5-item questionnaire related to nightmares; scores range from 0-20 with higher score indicates more severe nightmare symptoms.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

  12. Columbia Suicide Severity Rating Scale (CSSR-S)

    Questionnaire used for suicide risk assessment; categorizes level of suicide risk (low, moderate, high) based on responses to questions about suicidal ideation and behavior.

    Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2028, 35 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 35 months is close to that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

Start moved once since we started tracking on Sep 25, 2026: Jul 2025 → Aug 2025, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Aug 6, 2025was Jul 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • University of Colorado Anschutz Medical Campus · Aurora, United Statesno status→Recruiting
  • University of Colorado CCTSI CTRC · Denver, United Statesno status→Recruiting
Nov 6, 2026
Start date
Jul 2025→Aug 6, 2025 (actual)
Nov 6, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameBrachial artery flow-mediated dilation (FMD)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Nov 6, 2026
Secondary outcomes
13 time frame changed
What changed in the outcomes
  • Time frameLarge artery elastic stiffnessPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeLarge artery elastic stiffness-carotid arteryPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeAutonomic function-baroreflex sensitivityPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeAutonomic function- heart rate variabilityPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeBlood pressurePTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeEstimated glomerular filtration rate (eGFR)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeRenal vascular controlPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeRenal functional reservePTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomePittsburgh Sleep Quality Index (PSQI)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomePittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomePTSD Checklist for DSM-5 (PCL-5)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeNightmare Disorder Index (NDI)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
  • Time frameother outcomeColumbia Suicide Severity Rating Scale (CSSR-S)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • University of Colorado Anschutz Medical Campus · Aurora, United Statesno status→Recruiting
    • University of Colorado CCTSI CTRC · Denver, United Statesno status→Recruiting
    Start date Jul 2025→Aug 6, 2025 (now actual)
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameBrachial artery flow-mediated dilation (FMD)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    Secondary outcomes 13 time frame changed
    What changed in the outcomes
    • Time frameLarge artery elastic stiffnessPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeLarge artery elastic stiffness-carotid arteryPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeAutonomic function-baroreflex sensitivityPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeAutonomic function- heart rate variabilityPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeBlood pressurePTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeEstimated glomerular filtration rate (eGFR)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeRenal vascular controlPTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeRenal functional reservePTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomePittsburgh Sleep Quality Index (PSQI)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomePittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomePTSD Checklist for DSM-5 (PCL-5)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeNightmare Disorder Index (NDI)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    • Time frameother outcomeColumbia Suicide Severity Rating Scale (CSSR-S)PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured before and after 8 weeks of NightWare or sham conditions). → PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07021014
Collaborators
Ludeman Family Center for Women's Health Research
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Aug 6, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Emily Larson, PhD
Contact
emily.a2.larson@cuanschutz.edu
7205233224
Kerrie Moreau, PhD
Contact
kerrie.moreau@cuanschutz.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion